RxDoctor Payments Data

Douglas Rutan, DPM

Podiatrist · Vancouver, WANPI 1821081613

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations.

$1,140in general payments, 2019–2025

Across 65 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$251
  • Johnson & Johnson$132
  • GRT US Holding, Inc.$126
  • DJO, LLC$108
  • Treace Medical Concepts, Inc.$65
  • Nevro Corp.$64
  • plus $394 from 14 others

What the payments were for

  • Food & beverage$1,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,140 in reported general payments places this provider in the 55th percentile of 134 podiatrist providers in Washington.

See all podiatrist providers in Washington

Medicare billing

Part B allowed, 2024
$115,246
Medicare patients
206
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl12$186

Paid to pharmacies, not to this prescriber.

Other podiatrist in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →